It’s alive! ETFs as Frankenstein

It’s alive! ETFs as Frankenstein

Mark Stys had warned his client about the biomedical/pharmaceutical ETF called PJP—not because the stocks in it were a bad bet, but because the ETF was small and some of the stocks were thinly traded.